Our AI platform harnesses available, multi-omics, human disease data to quickly arrive at a short list of compound candidates, for the most responsive patients. Our platform also demonstrates consistently high predictivity; needing to initially test fewer than 30 predicted compounds in the lab. We are able to very quickly validate these top candidates by our engine in meaningful, deep functional assays before moving them forward. 

This enables rapid identification of the best drug candidates with the greatest possible chances of clinical translation and trial success.